TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subject inclusion criteria:~1. Patients with OTCD;~2. Age range: 7-60 years~3. Able to undergo neuroimaging safely (i.e. without presence of ferromagnetic devices)~4. Subject has a documented full scale IQ \> 70~Control participant inclusion criteria:~1. Healthy males and females without metabolic disease aged 7-60 years~2. Subject has a documented full scale IQ \> 70~Exclusion Criteria:~Subject exclusion criteria:~1. Mental retardation (i.e., Full Scale IQ\< 70)~2. Age range \<7 or \>60 years~3. Presence of ferromagnetic device(s) that preclude safe imaging~4. Pregnant female~Control exclusion criteria:~1. Subjects with a documented history of an intellectual deficit (i.e., Full Scale IQ\< 70)~2. Age range \<7 or \>60 years~3. Presence of ferromagnetic device(s) that preclude safe imaging~4. Pregnant female

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with OTCD (Type: None): males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing
- Healthy controls (Type: None): males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Calcium and Vitamin D on Bone Loss From the Hip

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~\>65 years calcium intake \< 1500 mg/day Willing to discontinue calcium and vitamin D pills for 2 months prior to enrollment~Exclusion Criteria:~Mentally incompetent, femoral neck BMD greater than 2 SD above/below age/sex-matched reference mean, 24-hr urine calcium/creatinine \> 300 mg/d women or \>350 mg/d men terminal illness, renal disease requiring treatment, kidney stone in the past 10 years, current hyperparathyroidism, treated with glucocorticoids, estrogen or androgen, fluoride, calcitonin, bisphosphonate, or any other treatment for osteoporosis.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Presence of acute uncomplicated type B aortic dissection~2. Able to tolerate endotracheal intubation and general anesthesia~3. Maximum transverse diameter of the descending thoracic aorta \< 55 mm and absence of descending thoracic aortic aneurysm, regardless of etiology.~4. Arterial anatomy is appropriate for stent graft therapy~Exclusion Criteria:~1. ASA classification = V~2. Severe renal insufficiency defined as SVS risk renal status = 3~3. Severe respiratory insufficiency defined as SVS risk pulmonary status = 3~4. Presence of connective tissue disease~5. Active infection or active vasculitides~6. Positive pregnancy test~7. Participation in another medical research study within 3 months of study enrollment~8. Myocardial infarction or cerebrovascular accident within 6 weeks prior to study enrollment~9. Planned concomitant surgical procedures (other than left subclavian artery transposition or bypass), or major surgery within 30 days of study enrollment~10. History of drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): TAG+BMT
- 2 (Type: ACTIVE_COMPARATOR): BMT alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Type 2 diabetes~* Treatment with metformin at a stable dose \>1500 mg/day~* HbA1c ≥ 7.0% and ≤10.0%~Exclusion Criteria:~* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)~* Type 1 diabetes, history of ketoacidosis, or hyperosmolar non-ketonic koma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Metformin + Saxagliptin
- 2 (Type: PLACEBO_COMPARATOR): Metformin + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a pre-menopausal woman aged between 18 and 48 years inclusive.~* Subject with a Body Mass Index ≥18 and ≤40.~* Subject with myomatous uterus size \< 16 weeks.~* Subject must have at least one uterine myoma of at least 3 cm diameter in size and no myoma larger than 10 cm diameter diagnosed by ultrasound.~* Subject complained of strong uterine bleeding.~* Subject is eligible for hysterectomy or myomectomy.~* Females of childbearing potential have to practice a non-hormonal method of contraception.~Exclusion Criteria:~* Subject has a history of or current uterus, cervix, ovarian or breast cancer.~* Subject has a history of endometrium hyperplasia or adenocarcinoma in a biopsy performed within the past 6 months or similar lesions in the screening biopsy.~* Subject has a known severe coagulation disorder.~* Subject has a history of treatment for myoma with a SPRM, including ulipristal acetate.~* Subject has abnormal hepatic function at study entry.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
- B (Type: EXPERIMENTAL): Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of hypercholesterolemia~* LDL-C \>/= 130 mg/dL but \</=250 mg/dL and triglyceride (TG) \</= 350 mg/dL~* National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guideline~Exclusion Criteria:~* Hypersensitivity to 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) inhibitors or Ezetimibe

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vytorin (Type: EXPERIMENTAL): Ezetimibe 10 mg/Simvastatin 20 mg
- Atorvastatin (Type: ACTIVE_COMPARATOR): Atorvastatin 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment was performed.~* Male or female Chinese participants ≥ 50 years of age at the time of screening.~* Active CNV lesions secondary to AMD that affect the central subfield (including retinal angiomatous proliferation lesions with a CNV component) in the study eye at screening and confirmed by the Central Reading Center (CRC).~* Total area of CNV (including both classic and occult components) must comprise \> 50% of the total lesion area in the study eye at screening and confirmed by the CRC.~* Intra and/or subretinal fluid affecting the central subfield of the study eye at screening and confirmed by the CRC.~* BCVA between 78 and 23 letters, inclusive, in the study eye at screening and baseline using ETDRS testing.~Exclusion Criteria:~* Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at baseline.~* Central subfield of the study eye affected by fibrosis or geographic atrophy assessed by color fundus photography at screening and confirmed by the CRC.~* Total area of fibrosis ≥ 50% of the total lesion in the study eye at screening and confirmed by the CRC.~* Subretinal blood affecting the foveal center point and/or ≥ 50% of the lesion of the study eye at screening and confirmed by the CRC.~* Previous treatment with any approved or investigational drugs for nAMD in the study eye (other than vitamin supplements).~* Retinal pigment epithelium rip/tear in the study eye at screening.~* Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to baseline.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brolucizumab 6 mg (Type: EXPERIMENTAL): 3 monthly intravitreal injections of brolucizumab 6 mg in the loading treatment period (q4w regimen) up to Week 8 followed by injections every 12 weeks (q12w regimen) or 8 weeks (q8w) up to Week 40 or Week 44, depending on disease activity status.
- Aflibercept 2 mg (Type: ACTIVE_COMPARATOR): 3 monthly intravitreal injections of aflibercept 2 mg in the loading treatment period (q4w regimen) up to Week 8 followed by injections every 8 weeks (q8w) up to Week 40.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present \>/= 1 month by history or exam~* BCVA is worse than 20/200 at time of screening~Exclusion Criteria:~* Corneal or lenticular abnormalities that preclude fundus observation~* Ongoing ocular infection, inflammation or history of herpetic corneal lesion~* Current or prior retinal detachment or retinal tears or breaks or intraocular tumor~* More than 1 severe vitreous hemorrhage within 6 months~* Previous vitrectomy for any reason~* Hemorrhage is exclusively pre-retinal, or old \& organized~* Prior Vitrase for intravitreal injection in either eye~* No light perception in either eye at any time~* Known contraindications to study medication~* Sickle cell disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitrase (Type: EXPERIMENTAL): A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.
- Observation (Type: NO_INTERVENTION): Observation only, no medication or intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women, aged 40 to 64 seeking treatment for menopausal symptoms~* At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels \> 40 mIU/mL~* Intact Uterus~Exclusion Criteria:~* Use of oral estrogen, progestin, androgen, or selective estrogen receptor modulator (SERM) containing drug products within 8 weeks before screening~* A history or active presence of clinically important medical disease: eg. cardiovascular disease (stroke, heart attack), chronic renal or liver disease, breast cancer, etc.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): bazedoxifene 20 mg/conjugated estrogens 0.45 mg
- 2 (Type: EXPERIMENTAL): bazedoxifene 20 mg/conjugated estrogens 0.625 mg
- 3 (Type: EXPERIMENTAL): bazedoxifene 20 mg
- 4 (Type: ACTIVE_COMPARATOR): Prempro
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interferon ß-1b Treatment by Cyclical Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients affected by remitting Multiple Sclerosis who had at least a relapse in the last year of the disease.~* Satisfying general clinical conditions according to the researcher. Adequate hepatic function. Capacity to use adequate contraceptive techniques during the study.~Exclusion Criteria:~* Any other disease that might better explain signs and symptoms of the patient.~* Any other disability condition that might interfere with the clinical evolution.~* History of hypersensitivity to natural or recombinant interferon or to human albumin.~* Clinically significant heart diseases and not controlled like dysrhythmias, angina pectoris or congestive heart failure.~* Not adequately controlled epilepsy.~* Inability, according to the examining commission, to grant a complete compliance with the protocol requirements for the whole study.~* Previous therapies modifying the disease course in the last six months.~* Steroid therapies in the last 3 months.~* Pregnancy, lactation, serological positivity to the pregnancy test during the screening period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- interferon beta cyclical administration (Type: EXPERIMENTAL): Interferon ß-1b Treatment by Cyclical Administration
- Interferon ß-1b Treatment (Type: ACTIVE_COMPARATOR): Interferon ß-1b Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study.~2. Female subjects must not be pregnant.~3. Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, or Mood Disorder~4. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months prior to screening.~5. Have moderate or severe TD~6. If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder, be on stable doses.~7. Be in general good health.~8. Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.~9. Have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids.~Exclusion Criteria~1. Have an active, clinically significant unstable medical condition within 1 month prior to screening.~2. Have a known history of substance dependence, substance (drug) or alcohol abuse.~3. Have a significant risk of suicidal or violent behavior.~4. Have a known history of neuroleptic malignant syndrome.~5. Have a known history of long QT syndrome or cardiac tachy-arrhythmia.~6. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).~7. Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.~8. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.~9. Have an allergy, hypersensitivity, or intolerance to tetrabenazine.~10. Are currently pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dose Group 1 (Type: EXPERIMENTAL): Fixed dose of NBI-98854 administered once daily for 48 weeks
- Dose Group 2 (Type: EXPERIMENTAL): Fixed dose of NBI-98854 administered once daily up to 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers, with a BMI 20-35 kg/m2 (males) and 20-30 kg/m2 (females).~Exclusion Criteria:~* Males: history, current or suspected prostate or breast cancer.~* Female: pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is able to provide written assent and the parents or legal guardian of the patient is able to provide written informed consent before beginning and study related procedures~* Patient has a documented clinical diagnosis of schizophrenia~* Patient's parent or legal guardian will be able to accompany the patient at each scheduled study visit~Exclusion Criteria:~* Patients (female) must not be pregnant or lactating~* Patients with a known intolerance or lack of response to previous treatment with quetiapine~* Patients who have previously participated in this study

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of ankylosing spondylitis~* Active ankylosing spondylitis~Exclusion Criteria:~* Complete ankylosis of spine~* Previous treatment with etanercept

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete